FibroGen and Fortis amend agreements, extend option exercise deadline to Dec 31, 2027

KYNTRA BIO, INC.

Amendments No.1 to Evaluation Agreement and Option Agreement & Plan of Merger executed March 28, 2025.
Original agreements dated June 6, 2024, as amended and restated from May 5, 2023.
Option exercise deadline under both agreements extended to December 31, 2027.
Full text of amendments to be filed with FibroGen's Q1 2025 10-Q.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.